309 related articles for article (PubMed ID: 33671730)
1. HBV/HDV Co-Infection: Epidemiological and Clinical Changes, Recent Knowledge and Future Challenges.
Sagnelli C; Sagnelli E; Russo A; Pisaturo M; Occhiello L; Coppola N
Life (Basel); 2021 Feb; 11(2):. PubMed ID: 33671730
[TBL] [Abstract][Full Text] [Related]
2. New therapies for hepatitis delta virus infection.
Loureiro D; Castelnau C; Tout I; Boyer N; Narguet S; Menasria Benazzouz S; Louis Z; Pons-Kerjean N; Giuly N; Marcellin P; Mansouri A; Asselah T
Liver Int; 2021 Jun; 41 Suppl 1():30-37. PubMed ID: 34155804
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
4. Management of HBV and HBV/HDV-Associated Liver Cirrhosis.
Höner Zu Siederdissen C; Cornberg M
Visc Med; 2016 Apr; 32(2):86-94. PubMed ID: 27413725
[TBL] [Abstract][Full Text] [Related]
5. Recent breakthroughs in the treatment of chronic hepatitis Delta.
Brancaccio G; Gaeta L; Vitale A; Gaeta GB
Infez Med; 2022; 30(2):204-210. PubMed ID: 35693059
[TBL] [Abstract][Full Text] [Related]
6. The Forgotten Virus, Hepatitis D: A Review of Epidemiology, Diagnosis, and Current Treatment Strategies.
Khattak A; Vongsavath T; Haque L; Narwan A; Gish RG
J Clin Exp Hepatol; 2024; 14(5):101395. PubMed ID: 38617106
[TBL] [Abstract][Full Text] [Related]
7. Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta.
Deterding K; Wedemeyer H
AIDS Rev; 2019; 21(3):126-134. PubMed ID: 31532397
[TBL] [Abstract][Full Text] [Related]
8. Pegylated Interferon α Therapy in Chronic Delta Hepatitis: A One-Center Experience.
Bahcecioglu IH; Ispiroglu M; Demirel U; Yalniz M
Hepat Mon; 2015 Mar; 15(3):e24366. PubMed ID: 25861318
[TBL] [Abstract][Full Text] [Related]
9. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
Heidrich B; Yurdaydın C; Kabaçam G; Ratsch BA; Zachou K; Bremer B; Dalekos GN; Erhardt A; Tabak F; Yalcin K; Gürel S; Zeuzem S; Cornberg M; Bock CT; Manns MP; Wedemeyer H;
Hepatology; 2014 Jul; 60(1):87-97. PubMed ID: 24585488
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
Castelnau C; Le Gal F; Ripault MP; Gordien E; Martinot-Peignoux M; Boyer N; Pham BN; Maylin S; Bedossa P; Dény P; Marcellin P; Gault E
Hepatology; 2006 Sep; 44(3):728-35. PubMed ID: 16941695
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hepatitis D: an unmet medical need.
Caviglia GP; Rizzetto M
Clin Microbiol Infect; 2020 Jul; 26(7):824-827. PubMed ID: 32120043
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis delta and HIV infection.
Soriano V; Sherman KE; Barreiro P
AIDS; 2017 Apr; 31(7):875-884. PubMed ID: 28121714
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis delta: immunopathogenesis and clinical challenges.
Grabowski J; Wedemeyer H
Dig Dis; 2010; 28(1):133-8. PubMed ID: 20460901
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.
Bogomolov P; Alexandrov A; Voronkova N; Macievich M; Kokina K; Petrachenkova M; Lehr T; Lempp FA; Wedemeyer H; Haag M; Schwab M; Haefeli WE; Blank A; Urban S
J Hepatol; 2016 Sep; 65(3):490-8. PubMed ID: 27132170
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options.
Lempp FA; Ni Y; Urban S
Nat Rev Gastroenterol Hepatol; 2016 Oct; 13(10):580-9. PubMed ID: 27534692
[TBL] [Abstract][Full Text] [Related]
16. A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction.
Suárez-Amarán L; Usai C; Di Scala M; Godoy C; Ni Y; Hommel M; Palomo L; Segura V; Olagüe C; Vales A; Ruiz-Ripa A; Buti M; Salido E; Prieto J; Urban S; Rodríguez-Frias F; Aldabe R; González-Aseguinolaza G
J Hepatol; 2017 Oct; 67(4):669-679. PubMed ID: 28527664
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.
Grabowski J; Yurdaydìn C; Zachou K; Buggisch P; Hofmann WP; Jaroszewicz J; Schlaphoff V; Manns MP; Cornberg M; Wedemeyer H;
Liver Int; 2011 Oct; 31(9):1395-405. PubMed ID: 21762356
[TBL] [Abstract][Full Text] [Related]
18. Screening for hepatitis D and PEG-Interferon over Tenofovir enhance general hepatitis control efforts in Brazil.
Goyal A; Romero-Severson EO
PLoS One; 2018; 13(9):e0203831. PubMed ID: 30192887
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study.
Manesis EK; Vourli G; Dalekos G; Vasiliadis T; Manolaki N; Hounta A; Koutsounas S; Vafiadis I; Nikolopoulou G; Giannoulis G; Germanidis G; Papatheodoridis G; Touloumi G
J Hepatol; 2013 Nov; 59(5):949-56. PubMed ID: 23850875
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis D virus replication is sensed by MDA5 and induces IFN-β/λ responses in hepatocytes.
Zhang Z; Filzmayer C; Ni Y; Sültmann H; Mutz P; Hiet MS; Vondran FWR; Bartenschlager R; Urban S
J Hepatol; 2018 Jul; 69(1):25-35. PubMed ID: 29524530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
